Pathologic assessment of the treatment effects of neoadjuvant therapy in patients with pancreatic cancer

Abstract

Pathologic assessment of the effects of treatment may provide important information about residual cancer cells, such as the presence of necrotic or viable cancer cells. It is expected that pathologic assessment of treatment effects is useful to predict patient outcomes, as well as to decide the treatment plan. We will show characteristic pathologic changes after neoadjuvant therapy and discuss three common pathologic evaluation systems.